Compare iShares MSCI Malaysia ETF (EWM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Malaysia ETF trades at $26.35 (market cap $256.41M), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1370× iShares MSCI Malaysia ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 65 Days and Merck & Co., Inc. for 98 Days on average.
| EWM | MRK | |
|---|---|---|
Market Cap | $256.41M | $351.28B |
Volume | 111,962 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $156.43 |
52-Week Low | $25.33 | $82.49 |
Typical Hold Time | 65 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM is trading at $26.61, down 1.88% today, with a bearish technical signal from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment. The stock lacks recent news coverage, creating uncertainty around current business developments and financial performance.
The outlook for EWM is cautious due to insufficient fundamental data and bearish technical indicators. Investment opportunities hinge on future earnings clarity, while risks include potential weak financials and negative market sentiment. Investors need updated SEC filings or analyst reports to gauge true valuation and growth prospects.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
